Renal Cell Carcinoma | Current Treatment: Physician Insights | US | 2020
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and angiogenesis inhibitors, immune checkpoint inhibitors are experiencing rapid uptake, and the trend toward combination therapies continues to increase. The approvals in 2019 of Keytruda (Merck & Co.) plus Inlyta (Pfizer) and Bavencio (Merck KGaA / Pfizer) plus Inlyta provide alternative options for patients. These therapies will compete with Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical) and Lenvima / Kisplyx (Eisai) plus Afinitor (Novartis). As uptake of these novel regimens increases, successful drug differentiation strategies will be crucial to ensure physician uptake and preference in this rapidly changing environment.
Questions Answered
- What are the drug-treatment rates across clinically and commercially relevant renal cell carcinoma patient populations?
- How has the addition of immune checkpoint inhibitors changed the treatment landscape for renal cell carcinoma? Which populations are most affected?
- How do physicians differentiate between combination therapies such as Opdivo plus Yervoy, Keytruda plus Inlyta, and Bavencio plus Inlyta? According to U.S. medical oncologists, what is the uptake of these regimens, and which combination is preferred?
- What factors drive or constrain the prescribing habits of U.S. medical oncologists?
Product Description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Geographies: United States.
Primary Research: Survey of 100 medical oncologists in the United States.
Key drugs covered: Opdivo, Yervoy, Keytruda, Inlyta, Bavencio, Cabometyx, Sutent, Votrient, Afinitor, Lenvima.
